The mostly unmet need as well as the pressure to show efficacy of new therapies to treat rare diseases contrasts with the limited possibility to use traditional statistical methods to design and analyse clinical trials in this setting
No takes yet. Share an insight, caveat, or question.
R.-D Hilgers (2016) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: